IMMU-17. REDUCING THE EX VIVO MANUFACTURING TIME OF EGFRVIII-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IMPROVES PHENOTYPE AND DEMONSTRATES POTENT ANTI-GLIOMA FUNCTION IN VIVO

Chimeric antigen receptor (CAR) T-cell therapy for glioma has been developed that targets EGFRvIII, HER2, EphA2, and IL13Rα2 antigens. Epidermal growth factor receptor variant III (EGFRvIII) is an attractive target for CAR therapy because its expression is tumor-restricted. Non-viral manufacturing o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Tanaka, Ryuma, Caruso, Hillary, Ling, Xiaoyang, Najjar, Amer, Heimberger, Amy
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2017
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692930/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.476
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge